Triptorelin reduces chemotherapy-induced early menopause in breast cancer

Share this article:

A gonadotropin-releasing hormone (GnRH) analogue can temporarily suppress ovarian function, subsequently warding off the occurrence of early menopause induced by chemotherapy among women with early-stage breast cancer.

Systemic treatments put premenopausal breast cancer patients at high risk of premature ovarian failure, with no standard strategies available to combat this adverse effect, according to investigators involved in the phase III trial, Prevention of Menopause Induced by Chemotherapy: A Study in Early Breast Cancer Patients—Gruppo Italiano Mammella 6 (PROMISE-GIM6) study (JAMA. 2011;306[3]:269-276). Earlier research had suggested that temporary ovarian suppression with a GnRH analogue during chemotherapy protects the ovaries in 67% to 96% of women with breast cancer receiving chemotherapy.

PROMISE-GIM6 enrolled 281 premenopausal, patients with stages I to III breast cancer from 16 sites in Italy between October 2003 and January 2008. The women, aged 24 to 45 years (median age 39 years), had had active menstrual cycles or normal menses in the 6 weeks prior to the start of chemotherapy. All were candidates for adjuvant or neoadjuvant chemotherapy.

Before beginning chemotherapy, 133 women were randomized to receive chemotherapy alone, and 148 to chemotherapy combined with the GnRH analogue triptorelin. Triptorelin 3.75 mg was administered intramuscularly at least 1 week before the start of chemotherapy and then every 4 weeks for the duration of chemotherapy.

One year after the last cycle of chemotherapy (last follow-up: August 18, 2009), 25.9% of the chemotherapy-only group experienced early menopause (defined as the absence of menstrual activity for at least 12 months with postmenopausal or unknown levels of FSH and E2), compared with just 8.9% of the triptorelin patients. This translated to an absolute reduction in early menopause occurrence of 17% for premenopausal patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

Approximately half of the chemotherapy-only women (49.6%; 60 women) had a resumption of menses, regardless of FSH and E2 levels, compared with 88 women (63.3%) in the triptorelin group—an absolute difference of 13.7%.

“In conclusion, our results suggest that temporarily suppressing ovarian function by administering triptorelin reduces the incidence of chemotherapy-induced early menopause,” wrote the PROMISE-GIM6 team. “This treatment can therefore be offered to premenopausal patients with breast cancer who wish to decrease the risk of permanent ovarian failure associated with chemotherapy.”

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.

Triple therapy revs up immune system against a common brain tumor

A triple therapy for glioblastoma, consisting of two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report.